Key result
B-type natriuretic peptide (BNP) effectively detected cardiac involvement in AL amyloidosis patients, yielding an area under the curve of 0.75 with 83% sensitivity and 70% specificity at a 412 pg/mL cut-off.
Why the study?
A useful biomarker for detecting cardiac amyloidosis had not been fully established in patients with light-chain amyloidosis.
Does BNP detect cardiac involvement and predict mortality in patients with AL amyloidosis?
Population
63 patients with AL amyloidosis
Comparison
Cardiac amyloidosis (n = 30) vs non-cardiac amyloidosis (n = 33)
Design
Observational cohort study
Authors
Loading...
May aid cardiac involvement detection in AL amyloidosis; leaves open prospective validation vs NT-proBNP.
Observational (n=63)
No
Does BNP detect cardiac involvement and predict mortality in patients with AL amyloidosis?
Effect estimate: AUC 0.75 (95% CI 0.61-0.90)
p-value: p=<0.001
BNP is a useful biomarker for detecting cardiac involvement and predicting all-cause mortality in patients with AL amyloidosis, potentially outperforming NT-proBNP and cardiac troponins in this population.
Kimishima et al. (2019) conducted an observational in AL amyloidosis (n=63). B-type natriuretic peptide (BNP) vs. Non-cardiac amyloidosis was evaluated on Detection of cardiac amyloidosis (AUC 0.75, 95% CI 0.61-0.90, p=<0.001). B-type natriuretic peptide (BNP) effectively detected cardiac involvement in AL amyloidosis patients, yielding an area under the curve of 0.75 with 83% sensitivity and 70% specificity at a 412 pg/mL cut-off.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: